Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitors

Dunn A, Dargaud Y, Abajas Y, Carcao M, Castaman G, Giermasz A, Hermans C, Jiménez-Yuste V, Lewandowska M, Mahlangu J, Meeks S, Miesbach W, Recht M, Salinas V, Chrisentery-Singleton T, Bonzo D, Mitchell IS, Wilkinson TA, Young G

Eptacog beta is a treatment used to control bleeding in people with hemophilia who have developed inhibitors to standard clotting factor therapy. In this clinical trial, rebleeding after treatment was rare, and when it occurred, it was usually controlled with just one additional dose of eptacog beta. No patients needed hospitalization for recurrent bleeding, supporting the therapy’s effectiveness and reliability for managing mild to moderate bleeding episodes.